Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103831
Status:
COMPLETED
Last Update Posted:
2010-03-02
First Post:
2005-02-15
Brief Title:
Oral Taxane in Combination With Pemetrexed Alimta in Patients With Recurrent Non-Small Cell Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase I Alimta Combination With BMS-275183 Oral Taxane
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase I-II dose ranging study of BMS-275183 oral taxane in combination with pemetrexed Alimta in patients with recurrent Non-Small Cell Lung Cancer NSCLC The safety and efficacy of this combination will be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None